Medical Technologist/ Ph.D/Hematology/Oncology/Molecular Biology/Genetics/Bioinfomatics/ISO
※Tweets and opinions are my own, and don't represent my department.
We want to revolutionize cancer treatment and we continue to advance our pipeline: the first patient has been treated in our BNT111 randomized Phase 2 trial. BNT111 is the lead product candidate from our proprietary FixVac platform.
TAPESTRY Study Results Fuel Calls for Universal Genetic Testing for Hereditary Cancer Risk. An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.
Our circulating tumor DNA (ctDNA) monitoring assay has been granted Breakthrough Device Designation by the FDA. Read more about how we are working to shape the future of clinical care and research through our innovative tests:
Hatoyama is, of course, famous for his lack of political sense. Prime Minister for less than one year, his real speciality is destroying every political party he joins
DESTINY-PanTumor01
Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations
✅Demonstrating significant anti-tumor activity and durable responses
➡️suggesting potential for broader application across various
Proud to share that we have now delivered 1 million reports, generated from our portfolio of CGP tests. Learn more about what this means for patients and the partners we serve in a blog from our CEO, Dr. Brian Alexander (
@xelamb
):
New FDA Approval – today we announced that our tissue-based genomic profiling test is now FDA approved to identify patients with solid tumors with RET gene fusions who may benefit from a
#TargetedTherapy
. Learn more about the announcement here: